Concord Biotech Limited Announces Resignation of Company Secretary and Compliance Officer

Concord Biotech Limited has informed stock exchanges about the resignation of its Company Secretary and Compliance Officer, marking a key managerial personnel change at the pharmaceutical company.

Key Personnel Change

Ms. Hina Patel has tendered her resignation from the position of Company Secretary and Compliance Officer (Key Managerial Personnel) of Concord Biotech Limited. The resignation was formally communicated to the National Stock Exchange of India Limited and BSE Limited on December 24, 2025, in compliance with regulatory requirements.

Parameter	Details
Name and Position	Ms. Hina Patel, Company Secretary and Compliance Officer (KMP)
Reason for Change	To pursue opportunities outside the organization
Effective Date	Close of business hours on January 21, 2026
Communication Date	December 24, 2025

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The disclosure follows the prescribed format under Regulation 30(6) and Schedule III Para A(7C) of the listing regulations.

Transition Arrangements

In her resignation letter dated December 24, 2025, Ms. Patel expressed gratitude for the trust, guidance, and support extended during her association with the company. She described her tenure as both professionally enriching and personally fulfilling. The outgoing Company Secretary has assured full cooperation during the transition period to ensure a smooth handover of responsibilities.

The company has been requested to file necessary forms with the Registrar of Companies, Ministry of Corporate Affairs, and submit intimations to stock exchanges as part of the resignation process. Ms. Patel extended her best wishes for the continued success of Concord Biotech Limited and expressed hope that the company achieves greater milestones in the future.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.13%	-0.02%	-4.95%	-26.76%	-39.05%	+42.91%

Concord Biotech Limited , a prominent player in the biotechnology sector, has announced the appointment of Mr. Raviraj Karia as its new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The appointment was approved by the Board of Directors in their meeting held on December 18, 2025, and is effective immediately.

New CFO Appointment Details

Parameter:	Details
Name:	Mr. Raviraj Karia
Position:	Chief Financial Officer (CFO) and Key Managerial Personnel (KMP)
Effective Date:	December 18, 2025
Board Meeting Duration:	12:10 PM to 12:50 PM
Approval Process:	Nomination and Remuneration Committee, Audit Committee, and Board of Directors

Professional Background and Expertise

Mr. Raviraj Karia brings extensive experience to his new role at Concord Biotech. As a Chartered Accountant, he has over 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity sectors. His career demonstrates deep expertise in corporate governance, strategic finance, and business partnering, having worked closely with Boards, Promoters, CEOs, and global leadership teams.

Career Highlights and Achievements

Experience Area:	Key Accomplishments
Organizations:	Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences
Major Deals:	Led India's largest outbound pharma acquisition, facilitated marquee private equity investments
Cost Optimization:	Reduced borrowing costs by 2-3% annually across multiple organizations
Global Operations:	Executed global audits across Europe, US, Latin America, and emerging markets
Technology Implementation:	SAP-based MIS, Power BI dashboards, GRC frameworks, VIM, and shared service centers

Strategic Impact and Leadership

Throughout his career, Mr. Karia has consistently enabled organizations to scale by strengthening financial discipline and implementing robust governance frameworks. He has delivered significant impact managing multibillion dollar financing programs and has driven major cost efficiency programs while optimizing working capital across various organizations.

Corporate Governance and Independence

The company has confirmed that Mr. Karia is not related to any of the Directors of the Company and does not hold any shareholding in Concord Biotech Limited. This appointment follows the earlier announcement of Mr. Lalit Sethi's planned retirement as CFO, which was scheduled for January 2026.

Management Transition

This appointment represents a smooth leadership transition for Concord Biotech, with the new CFO bringing substantial experience in the pharmaceutical and healthcare sectors. The immediate effective date suggests the company has successfully managed the transition process ahead of the previously announced timeline for the outgoing CFO's retirement.